Enzymatic synthesis of lactosylated and sialylated derivatives of epothilone A
Epothilone A is a derivative of 16-membered polyketide natural product, which has comparable chemotherapeutic effect like taxol. Introduction of sialic acids to these chemotherapeutic agents could generate interesting therapeutic glycoconjugates with significant effects in clinical studies. Since, most of the organisms biosynthesize sialic acids in their cell surface, they are key mediators in cellular events (cell-cell recognition, cell-matrix interactions). Interaction between such therapeutic sugar parts and cellular polysaccharides could generate interesting result in drugs like epothilone A. Based on this hypothesis, epothilone A glucoside (epothilone A 6-O-β-D-glucoside) was further decorated by conjugating enzymatically galactose followed by sialic acids to generate epothilone A 7-O-β-D-glucopyranosyl, 4′-O-α-D-galactoside i.e., lactosyl epothilone A (lac epoA) and two sialosides of epothilone A namely epothilone A 7-O-β-D-glucopyranosyl, 4′-O-α-D-galactopyranosyl 3″-O-α-N-acetyl neuraminic acid and epothilone A 7-O-β-D-glucopyranosyl, 4′-O-α-D-galactopyranosyl 6″-O-α-N-acetylneuraminic acid i.e., 3′sialyllactosyl epothilone A: 3′SL-epoA, and 6′sialyllactosyl epothilone A: 6′SL-epoA, respectively. These synthesized analogs were spectroscopically analyzed and elucidated, and biologically validated using HUVEC and HCT116 cancer cell lines.
KeywordsChemotherapeutic agent Epothilone A 6-O-β-D-glucoside 3′Sialyllactosyl epothilone A 6′sialyllactosyl epothilone A Epothilones
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2014R1A2A2A01002875).
- 1.Akbari, V., Moghim, S., Reza, M.M.: Comparision of epothilone and taxol binding in yeast tubulin using molecular modeling. Avicenna J. Med. Biotechnol. 3, 167–175 (2001)Google Scholar
- 11.Tanaka, M., Kataoka, H., Yano, S., Ohi, H., Kawamoto, K., Shibahara, T., Mizoshita, T., Mori, Y., Tanida, S., Kamiya, T., Joh, T.: Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells. BMC Cancer 13, 237 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Varki, A., Schauer, R., Sialic acids. In: Verki, A., Cummings, R. D., Esko, J. D.; et al.: editors. Essentials of glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 14. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1920/
- 24.Park, H.J., Zhang, Y., Georgescu, S.P., Johnson, K.L., Kong, D., Galper, J.B.: Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insight into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev. 2, 93–102 (2006)CrossRefPubMedGoogle Scholar
- 30.Vahdat, L. T.: Slinical studies with epothlones for the treatment of metastatic breast cancer. Semin. Oncol. 35, S22-30Google Scholar
- 36.Hata, K., Koseki, K., Yamaguchi, K., Moriya, S., Suzuki, Y., Yingsakmongkon, S., Hirai, G., Sodeoka, M., von Itzstein, M., Miyagi, T.: Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob. Agents Chemother. 52, 3484–3481 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Cowan, C. B., Patel, D.A., Good, T. A.: Exploring the mechanism of beta-amyloid toxicity attenuation by multivalent sialic acid polymers through the use of mathematical models. J. Theor. Biol. 258, 189–197Google Scholar